Androgen News and Research RSS Feed - Androgen News and Research

New discovery may soon make prostate cancer cells easier to destroy

New discovery may soon make prostate cancer cells easier to destroy

A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy. Drugs that could capitalize on the discovery are already in the pipeline, and a clinical trial to test whether the finding could improve treatments for prostate cancer patients could be only a few years away. [More]
High testosterone levels in women may increase uterine fibroid risk

High testosterone levels in women may increase uterine fibroid risk

Women who have high levels of both testosterone and estrogen in midlife may face a greater risk of developing benign tumors on the uterus called uterine fibroids than women with low levels of the hormones, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. [More]
ESSA reports net loss of $11.5 million for year ended September 30, 2015

ESSA reports net loss of $11.5 million for year ended September 30, 2015

ESSA Pharma Inc. today reported financial results for the year ended September 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with International Financial Reporting Standards ("IFRS"). [More]
Androgen deprivation therapy elevates Alzheimer’s risk

Androgen deprivation therapy elevates Alzheimer’s risk

US researchers find that androgen deprivation therapy increases the risk of Alzheimer’s disease in men with prostate cancer, with the risk rising with greater duration of therapy. [More]
Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

Men taking androgen deprivation therapy (ADT) for prostate cancer were almost twice as likely to be diagnosed with Alzheimer's disease in the years that followed than those who didn't undergo the therapy, an analysis of medical records from two large hospital systems by Penn Medicine and Stanford University researchers has shown. [More]
Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium. [More]
Finding may lead to better understanding of male genital birth defects

Finding may lead to better understanding of male genital birth defects

University of Florida Health researchers have identified genes that are disrupted by abnormal hormone signaling at crucial points during development, a finding that may lead to a better understanding of how the most common male genital birth defects arise in humans. [More]
Men with prostate cancer get stronger bones from playing football

Men with prostate cancer get stronger bones from playing football

Men with prostate cancer run the risk of brittle bones as a side-effect of their treatment. But one hour's football training a few times a week counters many of the negative effects of the treatment, according to University of Copenhagen scientists. [More]
MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

Researchers at the UC Davis Comprehensive Cancer Center have shown that the microRNA, miR-124, reduced tumor growth and increased cell death in castration-resistant prostate cancer. [More]
Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease. [More]
Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture. [More]
Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Inc. announced today that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital. [More]
Genetic discovery sheds light on how prostate cancer develops and spreads

Genetic discovery sheds light on how prostate cancer develops and spreads

A new and important genetic discovery, which sheds light on how prostate cancers develop and spread, has been made by an international research team led by scientists at The University of Nottingham. [More]
Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery. [More]
Prostate Cells Undergo 'Reprogramming' To Form Tumors, Study Finds

Prostate Cells Undergo 'Reprogramming' To Form Tumors, Study Finds

Scientists have gained a key insight into how prostate tumors get their start - not by rewriting the normal DNA code, but by reprogramming the master regulator of genes in prostate cells to drive malignant growth. [More]
New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Two new studies by cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor genes. [More]
UH researcher investigates two new avenues for detection, treatment of prostate cancer

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that. [More]
Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone). [More]
Study uses genome- and epigenome-editing tools to determine disease-causing variants

Study uses genome- and epigenome-editing tools to determine disease-causing variants

A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk. [More]
Researchers examine potential effects of sex development disorders in children, adolescents

Researchers examine potential effects of sex development disorders in children, adolescents

While it may not shock you to learn that children born with disorders of sex development (DSD) face challenges, Concordia University researchers have confirmed that these go far beyond the physical. [More]
Advertisement
Advertisement